Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.

Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 01/2009; 53(3):1170-6. DOI: 10.1128/AAC.01117-08
Source: PubMed

ABSTRACT There are limited data describing the concentrations of zidovudine, lamivudine, and nevirapine in nursing infants as a result of transfer via breast milk. The Kisumu Breastfeeding Study is a phase IIb open-label trial of prenatal, intrapartum, and postpartum maternal treatment with zidovudine, lamivudine, and nevirapine from 34 weeks of gestation to 6 months postpartum. In a pharmacokinetic substudy, maternal plasma, breast milk, and infant dried blood spots were collected for drug assay on the day of delivery and at 2, 6, 14, and 24 weeks after delivery. Sixty-seven mother-infant pairs were enrolled. The median concentrations in breast milk of zidovudine, lamivudine, and nevirapine during the study period were 14 ng/ml, 1,214 ng/ml, and 4,546 ng/ml, respectively. Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively. Therefore, lamivudine and nevirapine, but not zidovudine, are transferred to infants via breast milk in biologically significant concentrations. The extent and effect of infant drug exposure via breast milk must be well understood in order to evaluate the benefits and risks of maternal antiretroviral use during lactation.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Of the 5 types of viral hepatitis (HAV-HEV), HBV and HCV are by far the most common causes of chronic hepatitis in both pregnant and nonpregnant populations, causing more than 50% of cirrhosis cases and 78% of cases of primary liver cancer. Infection during pregnancy can have adverse effects on both the mother and her fetus. For all 5 viral hepatitis syndromes, early identification allows appropriate measures to be taken to optimize pregnancy outcomes and minimize the risk of perinatal transmission. This article reviews the prevention and management of all 5 viral hepatitis syndromes during pregnancy. Copyright © 2014 Elsevier Inc. All rights reserved.
    Obstetrics and Gynecology Clinics of North America 11/2014; 41(4). DOI:10.1016/j.ogc.2014.08.004 · 1.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An estimated 260,000 children under the age of 15 years acquired HIV infection in 2012. As much as 42% of mother-to-child transmission is related to breastfeeding. Antiretroviral prophylaxis for mothers or infants has the potential to prevent mother-to-child transmission of HIV through breast milk.
    Cochrane database of systematic reviews (Online) 10/2014; 10(10):CD011323. DOI:10.1002/14651858.CD011323 · 5.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine HIV-1 subtypes and transmitted HIV-1 drug resistant mutations among HIV-1 positive children born to HIV positive mothers in Busia County, blood samples were collected from 53 children aged between 6 weeks to 5 years in 2011. Their mothers were HIV-1 positive and on antiretroviral therapy at the time the children were born. The samples were analyzed for HIV-1 drug resistance and subtypes through sequencing of portions of the HIV-1 pol gene. The generated sequences were analyzed for subtype diversity using the REGA and BLAST subtyping tools. HIV-1 drug resistance was determined using the Stanford University HIV database. Of the 53 samples that were successfully amplified and sequenced, 69.8 % (37/53) were determined to be HIV-1 subtype A, 22.6 % (12/53) were subtype D, 5.6 % (3/53) subtype C and 1.8 % (1/53) subtype A1C. The prevalence of HIV-1 drug resistance mutations of any kind was 22.6 % (12/53).
    AIDS Research and Human Retroviruses 08/2014; DOI:10.1089/AID.2014.0158 · 2.46 Impact Factor

Full-text (2 Sources)

Available from
Jun 1, 2014